Cumberland Pharmaceuticals (CPIX) Set to Announce Quarterly Earnings on Thursday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is scheduled to be releasing its earnings data after the market closes on Thursday, November 7th. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Cumberland Pharmaceuticals Stock Performance

Shares of Cumberland Pharmaceuticals stock opened at $1.18 on Wednesday. Cumberland Pharmaceuticals has a 52 week low of $1.07 and a 52 week high of $2.36. The company has a quick ratio of 1.26, a current ratio of 1.44 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $16.64 million, a P/E ratio of -1.62 and a beta of 0.22. The company has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.41.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a research report on Saturday. They set a “hold” rating for the company.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.